Influence of metastatic sites and burden on oncological outcomes in patients progressing to metastatic castration resistant prostate cancer.

ABSTRACT:

Purpose

Metastatic castration-resistant prostate cancer (mCRPC) patients harbor reduced life expectancy after first-line treatment progression. Currently, no information is available regarding the influence of metastatic sites and osseous burden on progression-free (PFS) and overall survival (OS) of mCRPC patients.

Methods

We relied on the Frankfurt Metastatic Cancer Database of the Prostate (FRAMCAP) database to select patients progressing to mCRPC and stratified them according to lymph node vs. osseous vs. visceral metastatic sites. Moreover, we stratified osseous mCRPC patients regarding the number of metastatic lesions. Endpoints were PFS and OS in uni- and multivariable Cox regression models.

Results

Of 363 patients, 9.4% harbored M1a vs. 78% M1b vs. 12% M1c mCRP

SUBMITTER: Wenzel M 

PROVIDER: S-EPMC11531415 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature